CD68 and colorectal carcinoma: More recently, Feng et al. also evidenced that, within stage II CRC patients which underwent radical resection, CD206/CD68 ratio can identify those with high risk of recurrence and poor prognosis and might benefit from adjuvant chemotherapy (50).